Literature DB >> 10761802

The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.

A Melidonis1, A Stefanidis, S Tournis, S Manoussakis, S Handanis, M Zairis, L Dadiotis, S Foussas.   

Abstract

BACKGROUND: Many clinical and laboratory observations give support to the hypothesis that strict metabolic control by insulin infusion during acute coronary events may improve the ischemic damage and prognosis. HYPOTHESIS: We investigated the impact of intensive insulin treatment on fibrinolytic parameters during an acute ischemic myocardial event (unstable angina or acute myocardial infarction) in patients with type 2 diabetes mellitus.
METHODS: The study group consisted of 48 type 2 diabetic patients, of whom 24 were randomized to conventional therapy plus intensive insulin treatment (Group 1) and 24 to conventional therapy only (Group 2). The two groups were comparable according to gender, age, body mass index, waist:hip ratio, duration of diabetes, previous antidiabetic treatment, type of ischemic events, concomitant therapy, and the classic risk factors for coronary disease. Insulin-treated patients were excluded from the study. Plasma levels of fibrinogen, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1) were measured on admission and discharge. Fibrinogen (fibr) was measured using the photometric method. PAI-1 and t-PA were measured by enzyme-linked immunosorbent assays.
RESULTS: T-PA increased in both groups during hospitalization (t-PA(admission) vs. t-PA(discharge): Group 1: 15.42 +/- 4.4 ng x ml(-1) vs. 21.2 +/- 5.74 ng x ml(-1), p = 0.000037; Group 2: 14.47 +/- 6.31 ng x ml(-1) vs. 19.18 +/- 6.88 ng x ml(-1), p = 0.001). On the other hand, fibr and PAI-1 levels increased remarkably in controls (Group 2, fibr(admission) vs. fibr(discharge): 2.98 +/- 1.04 g x l(-1) vs. 3.59 +/- 1.01 g x l(-1), p = 0.002, and PAI-1admission vs. PAI-1 discharge: 30.6 +/- 17.34 ng x ml(-1) vs. 40.62 +/- 23.48 ng x ml(-1), p = 0.003). This finding was not observed in the intensive insulin treatment group (Group 1, fibr(admission) vs. fibr(discharge): 2.87 +/- 0.73 g x l(-1) vs. 2.67 +/- 0.72 g x l(-1), p = 0.101, and PAI-1 admission vs. PAI-1 discharge: 30.75 +/- 15.81 ng x ml(-1) vs. 27.75 +/- 6.43 ng x ml(-1), p = 0.484).
CONCLUSION: Intensive insulin treatment during an acute coronary event improves fibrinolytic profile in patients with diabetes mellitus. This is a possible mechanism for the reduced short- and long-term mortality in diabetic patients treated with intensive insulin treatment protocol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761802      PMCID: PMC6654905          DOI: 10.1002/clc.4960230306

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

Review 1.  Potential beneficial mechanisms of insulin (glucose-potassium) in acute myocardial infarction.

Authors:  I C C van der Horst; F Zijlstra
Journal:  Neth Heart J       Date:  2005-06       Impact factor: 2.380

Review 2.  The impact of antidiabetic therapies on cardiovascular disease.

Authors:  Brandy Panunti; Biju Kunhiraman; Vivian Fonseca
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

Review 3.  Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Bianca Hemmingsen; Søren S Lund; Christian Gluud; Allan Vaag; Thomas Almdal; Christina Hemmingsen; Jørn Wetterslev
Journal:  BMJ       Date:  2011-11-24

4.  Effect of insulin treatment on pulsatility ratio and resistance index of the retinal artery in patients with type 2 diabetes.

Authors:  Tsuneaki Omae; Youngseok Song; Takafumi Yoshioka; Tomofumi Tani; Akitoshi Yoshida
Journal:  PLoS One       Date:  2021-07-20       Impact factor: 3.240

Review 5.  Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature.

Authors:  Sofie Meijering; Anouk M Corstjens; Jaap E Tulleken; John H J M Meertens; Jan G Zijlstra; Jack J M Ligtenberg
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

6.  How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool.

Authors:  Isabelle Ettori-Ajasse; Elise Tatin; Gordon Forbes; Sandra Eldridge; Clarisse Dibao-Dina
Journal:  Trials       Date:  2020-03-19       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.